Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Bioferon vs Rebif in Healthy Subjects
NCT02517788Phase 1Completed
- Sponsor
- Lausanne University Hospital
- Start
- May 2006
- Primary completion
- Jul 2006
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, randomised, open-label trial of interferon beta-1a HSA+ biosimilar in relapsing-remitting multiple sclerosis (RRMS) (5 arms), sponsored by Lausanne University Hospital. Primary endpoint: Composite of interferon beta-1a PK parameters. Started May 2006; status: completed.
02
Drugs
interferon beta-1a HSA+ biosimilar
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02517788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02517788.